HIMS.K

HIMS.K has a market price of $26.70, resulting in a market capitalization of $6.17 billion. The company's price-to-earnings ratio is 48.06, and its price-to-book ratio is 11.41, indicating a premium valuation relative to its book value. The enterprise value to EBITDA ratio is 65.46, suggesting a high valuation relative to its earnings before interest, taxes, depreciation, and amortization. In terms of profitability, HIMS.K has a return on equity of 23.73% and a return on assets of 5.96%. These figures indicate that the company is generating a relatively high return on its equity but a moderate return on its assets. The company's gross profit margin is 73.8%, and its operating margin is 4.5%, which are key metrics for assessing its profitability. HIMS.K's revenue is concentrated in the healthcare sector, with no specific geographic breakdown provided in the available data. The company's capital structure includes $972.58 million in long-term debt and $228.62 million in cash and equivalents, resulting in a debt-to-equity ratio of 1.8. The company's liquidity is rated as medium, with a current ratio of 1.9. The company's growth trajectory is reflected in its revenue of $2.35 billion and net income of $128.37 million. The company's free cash flow is negative at -$59.72 million, indicating that it is not generating sufficient cash from operations to cover its capital expenditures. The company's capital expenditures amounted to $242.59 million, which is a significant investment in its operations. HIMS.K faces a medium liquidity risk, as indicated by its current ratio of 1.9. The company's risk assessment also highlights a key flag: net cash is negative after subtracting total debt, which suggests potential liquidity constraints. The company's dilution risk is rated as low, with no significant dilution potential identified. Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's analyst estimates indicate a mean price target of $26.30, with a median price target of $25.25. The mean recommendation from analysts is 2.71, indicating a generally neutral stance, with 5 buy recommendations and 12 hold recommendations.